Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

Ejlertsen, Bent; Offersen, Birgitte Vrou; Overgaard, Jens; Christiansen, Peer; Jensen, Maj‐Britt; Kroman, Niels; Knoop, Ann; Mouridsen, Henning T.

doi:10.1080/0284186x.2017.1408962

Cited by 18 publications

(18 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DBCG RT Committee expects the study to provide an evidence-based introduction to SDM in RT departments across Denmark. This is in line with the DBCG tradition of introducing new treatments or strategies through national, evidence-based trials [25][26][27][28]. The hypothesis is that SDM supported by a customized PtDA will increase patient-reported engagement in the decision making on adjuvant RT and thus enhance patient agency in an important life decision.…”

Section: Introductionsupporting

confidence: 63%

Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM)

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 63%

Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM)

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…4 During the last 30 years the prognosis of breast cancer has improved substantially, and the treatment of breast cancer has also changed considerably with more adjuvant treatment and less extensive surgery. 16 The generalisability of the results from studies with patients diagnosed in the 90's and earlier to patients today is therefore questionable. Further, these earlier studies only made rather crude adjustments for disease characteristics.…”

Section: Discussionmentioning

confidence: 99%

“…The Danish Breast Cancer Group (DBCG) database is a nationwide clinical breast cancer database initiated in 1977. 16 Previous quality assessments of the database have shown a near complete registration of breast cancer cases. 17,18 Using the unique civil registration number assigned to all Danish citizens, info on diagnosis from the DBCG was linked to the Danish Pathology Register, which contains detailed information on all human tissues examined by a pathological department in Denmark.…”

Section: Registriesmentioning

confidence: 99%

Breast cancer mortality in synchronous bilateral breast cancer patients

et al. 2019

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Evidence suggests that patients with synchronous bilateral breast cancer (SBBC), diagnosed within 4 months, have an inferior prognosis compared to unilateral breast cancer (UBC) patients. Using data from nationwide Danish clinical databases, this cohort study investigated whether the inferior prognosis could be explained by SBBC patients having a more aggressive disease, or whether the prognosis could be explained by the fact that they have two simultaneous cancers. METHODS: Patients were diagnosed from 1999-2015. The main outcome was excess mortality, subtracting background population mortality from observed mortality. Differences between SBBC and UBC patients were evaluated by rate ratios (RR) and estimated by Poisson regression. RESULTS: In total, 1214 SBBC and 59 177 UBC patients were included. SBBC patients had a significantly higher excess mortality than UBC patients after adjustment for age and period (RR = 1.73; 95% CI:1.44-2.08; p < 0.01) and after adjusting for characteristics of the worst tumour as traditionally done (RR = 1.31; 95% CI:1.08-1.57; p = 0.01). However, adjusting for characteristics of both tumours, using a more advanced competing risks model, no difference was observed (RR = 1.01; 95% CI:0.83-1.22; p = 0.93). CONCLUSIONS: Our study does not support that the inferior prognosis in SBBC patients is due to having more aggressive tumours per se, but rather the combined effect of having two simultaneous cancers.

show abstract

“…This study used data from the Danish Breast Cancer Group (DBCG), a population-based clinical registry that has collected data on nearly all breast cancer patients in Denmark since 1977 [19,20]. The source population consisted of 11,251 female residents of the Jutland Peninsula in Demark with a primary breast cancer diagnosis of stage I, II, or III as defined by the Union for International Cancer Control (UICC) [21].…”

Section: Study Populationmentioning

confidence: 99%

Expression of survivin does not appear to influence breast cancer recurrence risk

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Survivin is an inhibitor of apoptosis, and its expression associates with poor outcomes in multiple cancers. It may be a therapeutic target due to its unique expression in cancer cells. Methods: We estimated the association between nuclear and cytoplasmic survivin expression in primary tumors and breast cancer recurrence. In this case-control study, we included women age 35-69, diagnosed with stage I-III breast cancer between 1985 and 2001, and registered with the Danish Breast Cancer Group. We identified 541 patients with breast cancer recurrence with estrogen receptor-positive disease who were treated with tamoxifen for at least 1 year (ERþ/TAMþ) and 300 with estrogen receptor-negative carcinomas, not treated with tamoxifen, and who survived at least 1 year (ERÀ/TAMÀ). Controls were matched to cases on ER/TAM status, date of surgery, menopausal status, stage and county. Survivin expression was estimated by immunohistochemistry on tissue microarrays. We fit logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) associating nuclear and cytoplasmic survivin expression with recurrence. Results: Associations between nuclear and cytoplasmic survivin expression and breast cancer recurrence were near-null in both ERþ/TAM þ and ERÀ/TAM À strata. For the cytoplasmic to nuclear ratio (CNR) of survivin expression, we found a null association in the ERþ/TAM þ group comparing CNR !5 with CNR <5, but an association (OR ¼2.48, 95% CI: 1.15, 5.31) in the ERÀ/TAM À group. Conclusions: Survivin expression was not associated with breast cancer recurrence in this study. The CNR ratio may warrant further investigation especially among ER À tumors.

show abstract

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

Abstract: The trials conducted and implemented by the DBCG appear to have a major impact on the substantial survival improvements in breast cancer.

Cited by 18 publications

References 108 publications

Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM)

Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM)

Breast cancer mortality in synchronous bilateral breast cancer patients

Expression of survivin does not appear to influence breast cancer recurrence risk

Contact Info

Product

Resources

About